

COPD risk stratification: Helping you to prioritise patients most in need.

This summary has been written by GSK with consultation and approval from the Joint Working Project Team.

Frimley Health and Care Integrated Care System and GSK are undertaking a Joint Working project. The aims are to:

- Help primary care to identify and prioritise for review patients who would benefit from referral and uptake of pulmonary rehab (those COPD patients who are symptomatic or have had an exacerbation and/or a hospital admission in the last 12 months).
- Support delivery of reviews in line with local ‘Medicines Management of Stable COPD’ guidelines including alignment to local medicines optimisation priorities including a move towards lower carbon inhalers where clinically appropriate to improve the carbon footprint of inhaler use in Frimley ICS.

This involves a balance of contributions from both parties with the pooling of skills, experience and resources. The project will run in H2 2021.

Intended Benefits:

Patients	<ul style="list-style-type: none"> • Patients with highest need for a review are prioritised. • Full review in line with national and local guidelines based on risk stratification (patients may have not received a review otherwise or will receive quicker than when reviewed in yearly cycle) • Optimisation of both non-pharmacological & pharmacological management • Potentially fewer COPD- related interventions, including hospital admissions • Better informed about COPD management and treatment options • COPD managed in accordance with current best practice clinical guidance • Appropriate referral to pulmonary rehabilitation
NHS	<ul style="list-style-type: none"> • Support with risk stratification • Supports efficiency and effective use of available resources by identifying those patients at greatest need for review. • Reduced variability in practice approaches to patient identification and review. • Guideline implementation and consistent prescribing and non-prescribing recommendations, promoting learning for sustainability • Working towards achievement of carbon reduction aspirations • Potential cost savings • Able to plan services better for patients
GSK	<ul style="list-style-type: none"> • Broadening of customer network • Demonstrate partnership working • Potential increase in prescribing of on formulary DPI products within class if clinically appropriate for patients – which could include GSK products • Expansion of the COPD patient population who are managed according to current clinical and best practice guidelines as a result of the programme • Increase in the appropriate use of medicines licensed for COPD aligned to local or national guidance, with likely increase in the prescribing of GSK products as well as those of other pharmaceutical companies. • Better understanding of the challenges faced by the NHS in delivering high-quality patient services and care • Helps GSK to live its value of being a patient focussed company.